Document Detail


Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.
MedLine Citation:
PMID:  22570679     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Hyponatremia is a common problem in patients with advanced cirrhosis. It develops slowly (paralleling the rate of progression of the liver disease) and usually produces no neurological symptoms, although it may exacerbate hepatic encephalopathy. For patients awaiting liver transplantation a low serum sodium level is a strong predictor of pretransplant mortality, independent of the Model for End-stage Liver Disease score (MELD). The pathogenesis of hyponatremia is related to the hemodynamic changes and secondary neurohormonal adaptations that occur in patients with cirrhosis and ascites. The nonosmotic release of arginine vasopressin is the principle cause of the hyponatremia and vasopressin-receptor antagonists are a new class of drugs recently approved for treatment of cirrhotic hyponatremia. In this article we review the safety and efficacy of V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.
Authors:
Shahid Habib; Thomas D Boyer
Related Documents :
9863989 - Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulm...
16737989 - Computed tomography and pulmonary function abnormalities in sickle cell disease.
2211219 - Prospective study of long-term pulmonary manifestations of mantle irradiation.
8769509 - Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension...
22917679 - Evidence for alterations in central noradrenergic signaling in irritable bowel syndrome.
9350909 - Management strategies and determinants of outcome in acute major pulmonary embolism: re...
18435629 - Experience with over 1000 implanted ventricular assist devices.
12898929 - The level of total sialic acid, alfa-antitrypsin, ceruloplasmin in the serum of patient...
1736849 - In vivo phosphorus magnetic resonance spectroscopy in multiple sclerosis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Therapeutic advances in gastroenterology     Volume:  5     ISSN:  1756-2848     ISO Abbreviation:  Therap Adv Gastroenterol     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-09     Completed Date:  2012-07-10     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101478893     Medline TA:  Therap Adv Gastroenterol     Country:  England    
Other Details:
Languages:  eng     Pagination:  189-97     Citation Subset:  -    
Affiliation:
Department of Medicine, Section of Gastroenterology and Hepatology, University of Arizona College of Medicine, Tucson, AZ, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis ...
Next Document:  Secondary causes of nonalcoholic fatty liver disease.